Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat

Contributed by: PR Newswire

Tags

GESYNTA-PHARMA

More Like This

/C O R R E C T I O N -- Gesynta Pharma/

Gynica announces First-in-Human Clinical Trial of Novel IntraVag© Treatment for Endometriosis

PR Newswire associated0

Hope Medicine Inc. Announces Positive Results from a Global Phase 2 Study of a First-in-Class Endometriosis Treatment and Breakthrough Therapy Designation

Gedeon Richter: Medical Treatment of Endometriosis with a progressive approach

Organon to Present New Research on Access and Value at ISPOR 2026

Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints

Vertex Announces Key Advancements Across Kidney Portfolio

GlobeNewswire associated0

Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management